Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas.
about
MicroRNA miR-155 is a biomarker of early pancreatic neoplasiaGenetic abnormalities in pancreatic cancerMolecular detection of pancreatic neoplasia: Current status and future promisePancreatic adenocarcinoma pathology: changing "landscape"Pancreatic cancer.Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma.Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma.Genome-wide CpG island profiling of intraductal papillary mucinous neoplasms of the pancreas.Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays.Fascin overexpression in intraductal papillary mucinous neoplasms (adenomas, borderline neoplasms, and carcinomas) of the pancreas, correlated with increased histological grade.Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas.Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspectsPrecursor lesions of pancreatic cancer.Molecular signatures of pancreatic cancer.Pancreatic cancer DNMT1 expression and sensitivity to DNMT1 inhibitors.Reduction of pancreatic acinar cell tumor multiplicity in Dnmt1 hypomorphic mice.Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas.Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas.PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas.BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreasIdentifying molecular markers for the early detection of pancreatic neoplasia.Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms.Pancreatic cancer screeningEpigenetics and epigenetic alterations in pancreatic cancer.Genetic and epigenetic alterations of familial pancreatic cancers.Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas.Carcinogenesis of pancreatic adenocarcinoma: precursor lesions.Overexpression of ankyrin1 promotes pancreatic cancer cell growth.Emerging drugs in the treatment of pancreatic cancer.PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.Pancreatic cancer: gene therapy approaches and gene delivery systems.Molecular pathogenesis of pancreatic cancer and clinical perspectives.Acinar cell reprogramming: a clinically important target in pancreatic disease.Expression of claudin-4 (CLDN4) mRNA in intraductal papillary mucinous neoplasms of the pancreas.Diagnostic utility of aberrant methylation of tissue factor pathway inhibitor 2 in pure pancreatic juice for pancreatic carcinoma.Predicting the Grade of Dysplasia of Pancreatic Cystic Neoplasms Using Cyst Fluid DNA Methylation Markers.Effects of p16 gene on biological behaviours in hepatocellular carcinoma cells.CpG island methylation profile of pancreatic intraepithelial neoplasia.[Precursor lesions of pancreatobiliary cancer].Analysis of LKB1 mutations and other molecular alterations in pancreatic acinar cell carcinoma.
P2860
Q24649254-30D28BD3-5DC7-47CD-87A6-A3654DAC13F1Q24800194-7D401CC0-0A62-410B-A5AF-286FB7541058Q26777379-39B2D421-96BF-4557-A484-A5090A2608CBQ26799446-6F99D5E5-73FF-4307-9BC5-11956AC45663Q30490247-32F48F5E-A738-4483-A56F-7F302DBC71EAQ30491042-F937496D-3CFA-4E80-8616-4A183E2A7658Q30502257-6E820268-FD3C-461C-ACDD-47DC96F93330Q30504615-5D1EAFAE-9B8C-481A-A607-CCA6E458DFD9Q31121505-A4CED771-F0BF-42D1-912B-FA70E03F5380Q33280569-3496C40D-BAD9-40B9-92D8-FC71EFAB9855Q33754040-5E9C0DA9-D340-496D-ADE3-804231CAD377Q33801377-3A1382BE-8450-4337-9C64-42611E1D0E33Q33855814-44155834-836D-41C6-BF29-3E95A39E8E17Q33918801-66290EE0-83B7-4B69-9A24-3C44DA29D2ADQ34061112-E28B63DA-64B1-4072-8516-E35535B9A9A0Q35020444-0728E628-03DE-4BE5-85BA-9F6B878C0194Q35094629-AA304D9D-C1F3-4078-9A1B-F4255975788AQ35161198-E03D9CED-DB80-4C84-A8DB-57DE9724E3C3Q35606891-C7344336-8324-4066-96F2-989918B436D3Q35783104-2DA6311A-CAD6-4373-865F-D4EA1266FB55Q36328508-0E565A85-607F-40C1-9438-F989D967359EQ36670990-BC10E2EE-9B6B-4E6B-A3E5-BDDAACAAEA6DQ36896536-55AC520F-1B43-4F5F-8990-AF63AC0A8619Q37041763-181F2EFB-5AB2-4E95-8D53-7A137A0D3B00Q37148201-ECC7E30B-3174-49AD-972F-0DEC85FA2D16Q37183611-52639B0D-62F4-4A60-9BF8-D99D87E5D8A6Q37291172-49EE455B-111B-4CA9-BADA-1C21A098D3D4Q37376436-0124E50A-1880-4950-9313-A996F378096AQ37494647-748CABB7-0DA6-45B6-B743-55CA1A3EFD59Q37558625-1EE97ADA-4127-4029-A09E-CCD4238718D5Q37621562-EFF551DE-DEE9-4649-B57D-DDC4396E7819Q37960816-B4E41B1C-19C1-4D3B-9E65-12A0021CB94BQ38459854-908E1E45-D0BD-41CB-9C05-C149A8F2F604Q39628515-47EF85F6-4318-4A88-A985-C01A3748F68DQ40233356-D4E7B05B-80CB-4B4C-AE4B-36BCAD367A3CQ40440052-7FFB1668-BA91-4839-AF12-E0A3DB3046EDQ40679961-7A4CE077-1F01-4A21-973B-E10D0BB0A7ABQ42053166-21F78322-211C-4852-AC73-84904F0ACA01Q53220247-70C05AA2-622E-4E50-B1BE-A969D42D2B78Q54373054-BDCF2FEF-12AC-49F3-9CDE-59FFA1C24D04
P2860
Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Aberrant methylation of CpG is ...... ous neoplasms of the pancreas.
@en
Aberrant methylation of CpG is ...... ous neoplasms of the pancreas.
@nl
type
label
Aberrant methylation of CpG is ...... ous neoplasms of the pancreas.
@en
Aberrant methylation of CpG is ...... ous neoplasms of the pancreas.
@nl
prefLabel
Aberrant methylation of CpG is ...... ous neoplasms of the pancreas.
@en
Aberrant methylation of CpG is ...... ous neoplasms of the pancreas.
@nl
P2093
P50
P356
P1433
P1476
Aberrant methylation of CpG is ...... ous neoplasms of the pancreas.
@en
P2093
Charles J Yeo
John L Cameron
Norihiro Sato
Noriyoshi Fukushima
Takashi Ueki
P304
P356
10.1053/GAST.2002.34160
P407
P577
2002-07-01T00:00:00Z